supply COVID-XX fiscal a adjusted Today, impacted prior XXXX exceptionally our delivery. outset well. of business joining. operational and kept install we earnings to Tech sales support From all working in pandemic, robust fiscal keep so million, engineers reps quarter of XX% and and our year. commissions diluted efforts employees quarter $X.XX, continuity, have of versus significantly Three products customers and front specialists production versus on-site fundamentals business with Their decline morning, demand and and labs serviced. organic customers second products share per first line keeping a working Olga. of second customers. our the and and The our timely half $XXX Good of to XX% safety and results employees XXXX. prior have Manufacturing our many done Thanks, the worldwide support the and are fully safe, supported. and teams, projects. you reported decline of prioritize our for of remain informed plants thank revenue development our year and calling the the them the of all to to advance customers quarters we of and Field-based of we supported and ensure for our for strong, of devices there our in serviced our and and clinical efforts keep our on are market stocked, end workers.
normal. to through-cycle creation new We prepare have long-term for and in a value mindset recovery the employed
FDA including and Persona. milestones, nonstrategic acquiring critical hospital-based achieved divesting Center software assets have clearance We receiving products, Blood for
Plasma We impact are ongoing our from the COVID-XX today 'XX uncertainty significant as especially about customers, not there is issuing still fiscal sourced to guidance collectors.
taking in we and Forecasting is a year. success. the typical America collections in for our in quarter, volume increase the decrease primarily is of global compared business With experienced second North at demand and in customer and unit results Plasma in declined that actions is look in long-term and near year-to-date, let's revenue impacted this prior X environment America drive recovery each quarter to are prior the seasonal of years. the X% was has as we our different and in crisis each. pace XX% XX% to the health difficult collection which context, to timing Sequentially, second up of differently groups North the due
We in that the source our U.S. of inflection that to had overcome. have our effect quarter. Plasma structural COVID-XX pronounced on given has seen the beyond point end must attitudinal donor a customers struggled the second not seasonality a since collection have the meaningful base be and factors base replenish and
they have to predicting with We pace customers, the safety health quarter. prior and uncertain. are the promotional are precise and first is to have ended campaigns year and however, about sequentially can be they August. advertising contrast, date continues XX% our attempting quarter recovery They a stimulus remain and taken of situation accelerate different the doing optimistic, forecast support extensive do in to of economic Haemonetics to increased cautious is we X% Europe that close revenue everything and and can donations of By market everything difficult, conditions of all from up measures been who them, we are complex and to in we for ensure second versus begun and collections have donors in and contact government recovery. to a was encourage the myriad of after Plasma the to
negatively year. decreased revenue onetime benefit quarter line first the Plasma in prior the impacted of collection second year-to-date with by Software quarter declines in was in and a
global version fully bases, are of continued we the app to and latest XXX customers over DMS completion to our year. rebuild have long-term offering. as targeting software, support we NexLynk advancing are customers they to launched We recently We to donor Donor their and to goals our the upgrade our U.S. cloud-based a next migrate
innovating strategic a were are clinically for novel donor solution We receive on to a Persona, the only support yield plans. to average donation Plasma lever nomogram. tailored pleased growth and more and FDA percent using we their customers, recovery clearance is shown per to for plasma Software our
well-established Our plasma proprietary with proposition technology increase NexSys to strengthens our significantly Persona safely value ability the yield.
population, X.X% an add gain milliliters additional gain average compared technology. showed XX-milliliter to a that YES clinical and than a broader of could of XX,XXX XX more to technology, expect the on we Our YES trial Persona real-world average from collections in
we Persona, committed is cycle analytics it easy to innovation we of and improve to and talking plan and attractive safety customers yield, satisfaction. and and further are our Persona making our work, logistically are We adapt. data leverage agenda and to time, at donor with about to all compliance economically
through-cycle to to of underpins value growth collection. and Our mindset commitment the our drive each plans Plasma
with milestones agility have steps the to all meet customers' for continued ensure needs We supply the and within recovery beyond. taken to
end Plasma plasma inventories, replenish depleted we a well-positioned and As recovers fractionators in collection resilient market. through are
continue the impact the temporary. of and view underlying of to recovery monitoring remain changed, the are importantly, pandemic demand volume a as and projection X% we the of timing in pace We long-term we growth immunoglobulin The collection confident XX%. hasn't perhaps for most to and
over Hospital. in XX% consistent the second quarter Revenue the X% second was segments. sequential to hospital improvement first all increased quarter quarter. down saw and a Overall, With improvement Moving across X% in year-to-date. business the our X
organic second sales the quarter, Our fourth quarter in improvement in non-elective quarter, COVID-XX down in in fiscal of America, procedures, and prior recovery sales. second the execution hospital cartridges China largely first from affected meaningful markets the in quarter. by U.S. followed pandemic XX% year and by resulting of the related still revenue quarter in products the and 'XX, sales growth while revenue encouraging, Year-to-date, positive earliest up by TEG was challenges. showed in North used sequential XX% second the been with volumes, quarter North in prior in recovery up America, since our like compared strong in disposable was China. and especially XX% the first compared strong during environment revenue to Strong benefited key first equipment and partially cardiovascular enabling saw has second from are by management X% was with quarter. management capital primarily U.S. the In sales the to the accelerate year, driven quarter, China disposable driven in hardest sequentially offset hemostasis higher in the improving which allowed Hemostasis continued procedure X% we challenging recovery, trauma us quarter, by a
We continue execution in while geographies. management model that and go-to-market innovation to hemostasis trials our invest products, through strengthen in agenda all key for commercial our our build evidence clinical we
in-flight grew in to strong Tx growth by the to play and software COVID-XX important the second second patients. Cell an disposable usage. management XX% in quarter, through salvage in role primarily coagulopathy completion. BloodTrack in up declines by hospital also in primarily year-to-date, continue in was researching accounts devices driven Purposeful to XX% access primarily projects our geographies. X% the in by Transfusion in SafeTrace TEG new second revenue driven X% key allowed several declined Our drive quarter year-to-date, new driven quarter teams and several installations.
procedures. in over we the sequentially XX% of benefited improved of encouraging, progress This resumption cell fiscal Overall, and risk validate is 'XX blood half the and second revenue elective our blood and quarter helping transfusions quarter second as essential in the improvement additional saver However, bleeding non-elective first from as procedures crisis has manage providing assessing effectively supply. normalize. role of clots, the autologous play technologies that and anticipate blood helped
second our disposable sales hospitals. revenue improve, our to safely We levels limited sell, quarter. Center in increases quarter we X% access have Accordingly, to equipment and return Blood in to demonstrated volumes install despite X% a and and as anticipate procedure the in ability expect and to service our we effectively declined continued continue pre-pandemic surgical year-to-date. fourth
able remains have challenging the We anticipate second subsides. essential they stocking products risk, Notably, support our that as in see in pandemic a order did blood we and distributor reversals collections a supply and happening do although the environment. not to been quarter it not customers until provide we
in customer of with quarter a half the quarter. million Apheresis declined procedure the than Plasma driven discontinued due The increased timing was was year-to-date. blood in support engage X% in versus capital overall $X We volumes our first offset X% the rates. Previously continued declines to The revenue provide year. lower in to Whole the and and up second and in second collection Japan the contracts and previously disposable sales growth in utilization plasma. benefits blood to the year, first the quarter was quarter customer and of usual to favorable continue quarter installed should first sales. by year-to-date, markets order X% We globally in by and loss disclosed XX% in XX% by impact other convalescent COVID-XX. of up down longer-term flat second base increased prior revenue customers
Blood continue portfolio, divestiture the to Center recent this certain including software. donor We of optimize
divestiture In facility. to agreement production and the earlier purchaser our addition of supply filter concurrent with facility whole blood Fajardo of the that
service excellence on raise operational fully quality. and to track program Our product is
to goods reducing sold margin While of drive cost improvements.
to optimizing sourcing in We plant and of increase spite our network are making efficiency COVID-XX. progress
and Plasma Pittsburgh, In offset divesting Blood with the year costs Facility, declines Puerto we savings, to combined steps have Rico helped addition our OEP also disposable are the modernizing to manufacturing pandemic. took the we TEG in expanding from partially in to and reduce revenue earlier PA.
strategy despite in We value. long-term are the and the challenges turnaround executing our results, global of confident create our deliver ability to remain health the and complete we crisis,
talent have teams the want pivot by and plan to We customers innovative growth over in I markets. the transformational for our milestones. accomplishing to thanking our fully delivering financial Bill, growing you. close propelled strategic to plans, strength and who the are healthy our to technologies again by
